Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.

PURPOSE: The goal of this study was to determine the predictive value of prostate-specific antigen density (PSAD) plus Prostate Imaging Reporting and Data System (PI-RADS) category for the detection of clinically significant prostate cancer.

MATERIALS AND

METHODS

This retrospective study included 526 men without known prostate cancer (initial diagnosis group) and 133 men with prostate cancer grade group 1 (active surveillance group) who underwent magnetic resonance imaging-guided and/or systematic prostate biopsy procedures between August 2014 and October 2018. Prostate specific antigen (PSA), PSAD, and PI-RADS category were entered into logistic regression models for predicting clinically significant prostate cancer (grade group ≥2) at biopsy. Receiver operating characteristic curve analysis was performed to assess model accuracy.

RESULTS

The area under the curve (AUC) increased when PSAD was combined with PI-RADS in the initial diagnosis group (difference in AUC = 0.031; 95% confidence interval: 0.012, 0.050; P = 0.002) but not in the active surveillance group (difference in AUC = 0.016; 95% confidence interval: -0.040, 0.071; P = 0.579). When a PSAD threshold of 0.15 was applied, the frequency of clinically significant prostate cancer in patients with a PI-RADS score of 3 or lower decreased from 9.8% to 5.6% in the initial diagnosis group and from 10.7% to 2.7% in the active surveillance group.

CONCLUSIONS

The addition of PSAD improves the predictive performance of PI-RADS in men without known prostate cancer. A PSAD threshold of 0.15 can help to minimize the number of missed clinically significant prostate cancer cases in men with a PI-RADS score of 3 or lower who decide to defer biopsy.